PE20100746A1 - Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables - Google Patents

Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables

Info

Publication number
PE20100746A1
PE20100746A1 PE2009001300A PE2009001300A PE20100746A1 PE 20100746 A1 PE20100746 A1 PE 20100746A1 PE 2009001300 A PE2009001300 A PE 2009001300A PE 2009001300 A PE2009001300 A PE 2009001300A PE 20100746 A1 PE20100746 A1 PE 20100746A1
Authority
PE
Peru
Prior art keywords
camptotechin
biocompatible
biodegradable
pharmaceutical formulations
polymer conjugates
Prior art date
Application number
PE2009001300A
Other languages
English (en)
Inventor
James Rolke
Russell C Petter
Mao Yin
Emile Farhan
Aleksandr Yurkovetskiy
Gui Liu
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42243068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20100746(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of PE20100746A1 publication Critical patent/PE20100746A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN COMPUESTOS DE FORMULA I, DONDE R1 ES H, -C(O)-CH2-CH2-C(O)-OH Y EL OTRO ES -CO-CH2-CH2-C(O)-NH-CH2-C(O)-OCPT; R2 ES H, -C(O)-CH2-CH2-C(O)-OH; CPT ES CAMPTOTECINA; n ES 32-3320; m ES 0-833; k ES 1-216, DONDE k, m Y n SE SELECCIONAN DE MODO TAL QUE APROXIMADAMENTE 1-15% DEL COMPUESTO EN PESO ES CAMPTOTECINA; B) UN AGENTE DE ESTABILIZACION SELECCIONADO ENTRE SORBITOL, MANITOL, SACAROSA, LACTOSA, GLUCOSA, XILITOL, ENTRE OTROS; C) UNO O VARIOS TAMPONES SELECCIONADOS ENTRE CITRATO DE SODIO, ASCORBATO, GLICINA, EDTA, 3-(N-MORFOLINO)PROPANSULFONICO; D) UN TENSIOACTIVO SELECCIONADO ENTRE POLISORBATO 80, POLOXAMER 407, SOLUTOL HS 15, CLORURO DE BENZALCONIO. DICHA FORMULACION ES UNA TORTA LIOFILIZADA APROPIADA PARA ADMINISTRACION ENDOVENOSA UTIL EN EL TRATAMIENTO ANTINEOPLASICO Y ANTITUMORAL
PE2009001300A 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables PE20100746A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12138408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
PE20100746A1 true PE20100746A1 (es) 2010-11-04

Family

ID=42243068

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001300A PE20100746A1 (es) 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables

Country Status (9)

Country Link
US (2) US8491880B2 (es)
KR (1) KR20110102420A (es)
CN (1) CN102307473A (es)
AR (1) AR074584A1 (es)
CL (1) CL2009002167A1 (es)
PA (1) PA8853201A1 (es)
PE (1) PE20100746A1 (es)
TW (1) TW201036639A (es)
WO (1) WO2010068759A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528665A (ja) * 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
US20180157397A1 (en) * 2016-04-08 2018-06-07 Maxx Media Group, LLC System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display
CN109563215B (zh) * 2016-06-03 2021-11-19 诺灵生物医药科技(北京)有限公司 聚合物连接子及其用途
CA3041254A1 (en) 2016-10-19 2018-04-26 Invenra Inc. Antibody constructs
KR102312222B1 (ko) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
EP3802580A1 (en) 2018-06-05 2021-04-14 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793986A (en) 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
JPH01190636A (ja) 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
EP0654973A4 (en) 1992-07-21 1995-08-09 Gen Hospital Corp LYPHATIC TISSUE DRUG ADMINISTRATION SYSTEM.
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5612037A (en) 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
WO1996030386A1 (fr) 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Derives d'amidite et derives d'oligonucleotides
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6818630B1 (en) 1999-06-18 2004-11-16 Ml Laboratories Plc Biologically active materials
IL131074A0 (en) 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
US6822086B1 (en) 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP4813712B2 (ja) 1999-08-09 2011-11-09 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
ES2294026T3 (es) 2000-09-06 2008-04-01 Ap Pharma, Inc. Polimeros degradables de poliacetal.
US7838619B2 (en) 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
DE60329126D1 (de) 2002-02-20 2009-10-15 Beth Israel Hospital Konjugate mit biologisch abbaubarem polymer und verwendung dafür
AU2003254023A1 (en) 2002-07-19 2004-02-09 The General Hospital Corporation Oxime conjugates and methods for their formation and use
AU2003256613A1 (en) 2002-07-19 2004-02-09 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
EP2402036B1 (en) 2002-09-06 2018-02-14 Cerulean Pharma Inc. Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto
EP1608380A2 (en) 2003-03-31 2005-12-28 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
ES2365918T3 (es) 2003-09-05 2011-10-13 The General Hospital Corporation Conjugados de poliacetal-fármaco como sistema de liberación.
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
JP4840449B2 (ja) 2007-01-31 2011-12-21 中央電気工業株式会社 炭素材料およびその製造方法
EA020251B1 (ru) 2007-11-28 2014-09-30 Мерсана Терапьютикс, Инк. Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина
WO2010144881A1 (en) 2009-06-12 2010-12-16 The General Hospital Corporation Treatment of meningeal and neural diseases

Also Published As

Publication number Publication date
TW201036639A (en) 2010-10-16
US8491880B2 (en) 2013-07-23
CN102307473A (zh) 2012-01-04
CL2009002167A1 (es) 2010-10-15
US20100179181A1 (en) 2010-07-15
KR20110102420A (ko) 2011-09-16
AR074584A1 (es) 2011-01-26
PA8853201A1 (es) 2010-07-27
US20140004074A1 (en) 2014-01-02
WO2010068759A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
PE20100746A1 (es) Formulaciones farmaceuticas de conjugados de camptotecina-polimero biocompatibles y biodegradables
ECSP088240A (es) Composición de trazodona para administración una vez por día
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
AR108936A2 (es) Formulación subcutánea de anticuerpo anti-her2
AR056609A1 (es) Composiciones estabilizadas de carbonato de lantano
AR092470A1 (es) Formulaciones acuosas estables de adalimumab
PE20050175A1 (es) Peliculas consumibles oralmente de disolucion rapida que contienen un almidon modificado para la mejora de la resistencia al calor y a la humedad
ES2282062T1 (es) Composicion farmaceutica que contiene irbesartan.
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
HRP20110444T1 (hr) Formulacije paratiroidnih hormona i njihove uporabe
AR059113A1 (es) Composicion para administracion topica
PE20070210A1 (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20040499A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
ECSP105163A (es) Composiciones farmaceuticas de agonista parcial de 5ht4
EP2588116A4 (en) FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN
BR9810320A (pt) Composição farmacêutica sólida, contendo derivados de benzofurano
AR106776A1 (es) Composiciones de cuidado oral
NZ593190A (en) Factor viii formulations
PE20061077A1 (es) Composicion farmaceutica que comprende 7-terbutoxi-imino-metil-camptotecina
ECSP066808A (es) Solución oftálmica que comprende carboximetilcelulosa de sodio e hidroxipropilmetilcelulosa
AR077436A1 (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables.
PE20091715A1 (es) Variantes de igf-i pegiladas y composiciones que las contienen
PE20080153A1 (es) Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
ECSP077262A (es) Composicion antihistaminica

Legal Events

Date Code Title Description
FD Application declared void or lapsed